Impath

Impath was a leading provider of cancer-specific diagnostic and information services designed to improve the clinical management of cancer patients. The company offered a comprehensive menu of high-complexity diagnostic tests, including immunohistochemistry, flow cytometry, and molecular genetics, primarily serving community-based pathologists and oncologists. Beyond diagnostics, Impath leveraged its extensive database of cancer cases to provide information services to pharmaceutical and biotechnology companies for clinical trial design and outcomes research. The company was a pioneer in the field of predictive oncology before its assets were acquired by Genzyme in 2004 following financial restructuring. Its services were integral in identifying specific biomarkers to guide targeted cancer therapies. The acquisition allowed Genzyme to significantly expand its presence in the oncology testing market.